FDA Approves First Drug to Treat Fatty Liver Disease NASH
- FDA approves first drug, Rezdiffra, to treat serious liver disease called nonalcoholic steatohepatitis (NASH)
- NASH is a common liver inflammation caused by buildup of fat in liver cells
- Can lead to liver scarring and dysfunction over time
- Estimated 6-8 million in U.S. have NASH with moderate to advanced liver scarring
- Rezdiffra works by reducing liver fat accumulation; side effects include diarrhea and nausea
